Livongo Health has received a $52.5 million investment to broaden the reach of its digital health-management tools, including its flagship diabetes-management platform.
The Mountain View, Calif.-based company will further develop its diabetes-management platform, expand the platform to include other conditions and move into international markets with the financing influx, according to CEO Glen Tullman.
The company's diabetes tool, which includes connected glucose meters and app-based coaching, is currently used by 35,000 people. Livongo has partnerships with a slew of Fortune 500 companies, including FedEx and PepsiCo, to provide employees with the platform. It also has agreements with providers and payers to work with employees and customers.
The goal for everyone using the platform, Tullman said, is “empowerment”—allowing people to take charge of their own health. But that will require going beyond their current diabetes focus.
"If our goal is to keep people healthier, and we take care of their diabetes but we don't address their hypertension, high cholesterol or depression, then we haven't really made them healthier,” Tullman said.
Livongo hopes to provide a single comprehensive solution to manage those conditions, he said—which is important, since 70% of people over 50 with diabetes also have another condition.
Hypertension will be first area of Livongo's expansion, Tullman said, followed by high cholesterol, weight management, pre-diabetes and depression.
Livongo's technology reflects a healthcare industry trend of using data to help people make better health decisions, Tullman said. But Livongo isn't exactly big data.
“This is actually small, bite-sized, usable data," he said.
General Catalyst and Kinnevik lead the Series D funding round, announced Thursday.
